Specialty drug spending continues to tick up, led by AbbVie’s Humira and J&J’s Stelara — report

Spending on specialty drugs continues to grow, driven mostly by more people using them, but also by increasing prices.

Specialty drug spending jumped 14.1% year over year with 9.9% attributed to the number of claims, but the remaining 3.9% attributed to increased costs per claim, according to Pharmaceutical Strategies Group’s…
Click here to view original post